Recent Finacing
Recent Raise
Alzheon is a clinical-stage biopharmaceutical developing ALZ-801, an oral prodrug inhibiting toxic amyloid oligomer formation for early Alzheimer’s, running the APOE4/4-targeted Phase 3 APOLLOE4 trial and diagnostic assays.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
